West Pharmaceutical
734 hedge funds and large institutions have $26B invested in West Pharmaceutical in 2023 Q2 according to their latest regulatory filings, with 93 funds opening new positions, 253 increasing their positions, 269 reducing their positions, and 50 closing their positions.
96% more call options, than puts
Call options by funds: $52M | Put options by funds: $26.5M
86% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 50
8% more capital invested
Capital invested by funds: $24B → $26B (+$1.94B)
6% more funds holding
Funds holding: 695 → 734 (+39)
6% less repeat investments, than reductions
Existing positions increased: 253 | Existing positions reduced: 269
1.95% less ownership
Funds ownership: 93.72% → 91.76% (-2%)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
Top Buyers
| 1 |
Man Group
London,
United Kingdom
|
+$89.8M |
| 2 |
JP Morgan Chase
New York
|
+$34.7M |
| 3 |
AAM
Ardevora Asset Management
London,
United Kingdom
|
+$34.4M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$22.8M |
| 5 |
KBC Group
Brussels,
Belgium
|
+$21.5M |
Top Sellers
| 1 |
Neuberger Berman Group
New York
|
-$86.6M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$81.5M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$78.8M |
| 4 |
ProShare Advisors
Bethesda,
Maryland
|
-$69M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$60.5M |
WST Hedge Fund Activity: Q2 2023 in Review
734 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q2 2023, worth a combined $26B — up 8.1% from $24B a quarter earlier.
Buyers outnumbered sellers: 93 funds opened new WST positions and 50 closed out — a net gain of 43 holders — while 253 added to existing stakes and 269 trimmed.
The largest buyer was Man Group, opening a new position worth an estimated $89.8M. The largest seller was Neuberger Berman Group, cutting an estimated $86.6M.
- 734 institutional investors held West Pharmaceutical (WST) as of Q2 2023, up from 695 in Q1 2023.
- Funds reported $26B of West Pharmaceutical stock for Q2 2023, up 8.1% quarter-over-quarter.
- 93 funds opened new West Pharmaceutical positions in Q2 2023 and 50 closed out, a net change of +43 holders.
- The largest West Pharmaceutical buyer in Q2 2023 was Man Group, an estimated $89.8M added.
- The largest West Pharmaceutical seller in Q2 2023 was Neuberger Berman Group, an estimated $86.6M sold.
Based on aggregated 13F filings for Q2 2023.